SparingVision today announces that it has selected a second target as part of its strategic collaboration with Intellia Therapeutics, Inc.to develop novel genomic medicines utilizing CRISPR-based gene...
Read moreOncoDNA’s lab in France is the first in the EU to enable access to the C2inform test for clinical decision-making
Read moreEl estudio responde a la necesidad de validar científicamente la precisión de la tecnología de imagen en tres dimensiones (3D) frente a la tomografía computarizada (TC) convencional en el estadiaj...
Read moreThe EPI-CT study, which involved almost one million people, confirms that CT imaging, although largely beneficial, entails a small risk that needs to be minimised as much as possible
Read moreDC Fine Chemicals ha anunciado hoy su reciente convenio de colaboración con IQS-URL, institución de prestigio en el ámbito educativo y científico. Esta alianza estratégica tiene como objetivo pri...
Read moreAlfa Laval ha establecido una alianza estratégica con Aalborg CSP, una empresa con tecnología en el sector de Plantas Termosolares, con la que trabajará para desarrollar soluciones de almacenamient...
Read moreThermo Fisher Scientific today announced the formation of a strategic partnership with Flagship Pioneering to develop and commercially scale multiproduct platforms on an accelerated basis.
Read moreThe Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selectiv...
Read moreThis expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.
Read moreAlfa Laval, the global leader in heat transfer, centrifugal separation, and fluid handling, and Bisviridi, a new company part of the BioteCH4 group, the leading anaerobic digestion (AD) operator in th...
Read moreCollaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC
Read moreThe combined Group, named 3PBIOVIAN, will offer unparalleled end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for Drug Substance and Drug Pr...
Read more